Business Wire

OLX Autos Reaches US$1b in Second-hand Car Transactions

Share

Today, OLX Group, a leading global network of trading platforms, reveals that OLX Autos, an innovation leader for second-hand car trade in 10 countries across Asia and the Americas, has surpassed US$1 billion in sales since its formation in January 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210824005386/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

OLX Autos Infographic: global footprint, with key figures about its users, inspection centres and car sales.

Every month, around half a million cars are listed for sale by consumers and dealers on OLX Autos classifieds platforms In India, Indonesia, and Latin America. OLX Autos attributes its rapid growth to offering customer solutions for car sellers, car buyers, and dealers, via its integrated online and offline capabilities:

  • Car sellers benefit from access to free valuation of their car, through either an in-person inspection at one of 450+ authorised OLX Autos inspection centres or a remote inspection from the comfort of their driveway. A realtime online dealer auction reaching a network of over 13K car dealers means that sellers are offered a fair market price in under an hour, offering a trusted car selling service with immediate and guaranteed payment.
  • For buyers, OLX Autos offers the reassurance of a wide range of inspected and verified cars, and an option to buy "OLX Autos Certified" cars directly from OLX’s online classifieds platforms. Buyers can also opt for convenient services such as financing, insurance, and assistance with registration, which are being rolled out country by country.
  • Finally, OLX Autos provides car dealers a reliable and fairly-priced source of autos inventory.

By bringing offline and online services together into a unified customer experience, OLX Autos offers a simplified car transaction process that aims to bring trustworthiness and peace of mind to one of life’s most high-stakes transactions.

OLX Autos has further accelerated its product development and customer experience in response to the Covid-19 pandemic, developing proprietary technology to pioneer home and self-inspection services. In this way, car sellers can use their mobile phone to capture their car data, take photos, upload videos, record audio of the engine, and get the convenience of a fair valuation from the comfort of their own home.

Gautam Thakar, CEO of OLX Autos said: “At the heart of what we do is innovate to solve customer pain points, and we keep finding more ways to make the car transaction process as pain-free and satisfying as it can possibly be. Introducing home and self car inspections during Covid-19 has helped our customers cope with the lockdown period that hit many of our markets, when car inspection centres had to close their doors for a time.”

“We use data, technology, and artificial intelligence to provide to a seller the car’s fair price, while offering buyers insurance and guarantees to provide peace of mind during what otherwise can be one of life's most stressful transactions,” Thakar concluded.

OLX Autos History

OLX Autos’ journey started in 2018 with a minority investment by OLX Group in Frontier Car Group (FCG). A further $500m investment into FCG in 2019 made OLX Group a majority shareholder. Starting in January 2020, OLX and FCG blended operations in selected markets, rebranding from local brands to “OLX Autos” in most countries. For the first time in these countries, FCG’s ‘real world’ inspection centres were paired with OLX’s online car trading platforms, addressing the customers’ need of helping overcome barriers of buying or selling a car online from a stranger.

OLX Autos at a glance

  • Operations (online platforms, inspection centers) in 10 countries (alphabetical): Argentina, Chile, Colombia, Ecuador, India, Indonesia, Mexico, Pakistan, Peru, and the United States.
  • Every month, ~500K cars are listed on OLX Autos classifieds platforms by consumers and dealers
  • 450+ inspection centres offer free car inspection with a convenient and trusted car selling service and immediate payment in 1 hour for car sellers
  • Monthly inspections of ~50,000 cars
  • Network of 13K+ dealers
  • To date, OLX Autos has bought, sold, and inspected 400K+ cars. In FY21 ~100K cars were sold
  • 4.6K+ employees assisting customers transact their cars, in 3 continents and 10 markets
  • “Self-inspection” mobile app allows car sellers to inspect their own cars, and submit the data remotely - replicating the inspection center experience from the comfort of their own homes
  • After a first year accelerated with growth and innovation milestones, in March 2021, consumer internet and marketplace veteran Gautam Thakar (eBay, Shopping.com, Living Social) joined as OLX Autos global CEO, based in India - the largest of OLX Autos’ markets.

#END#

About OLX Autos

OLX Autos builds advanced trading platforms for buying and selling second-hand cars. It combines online and offline services in a simple one-stop solution - bringing convenience, safety, and peace of mind to car buyers and sellers alike, and across 10 countries and three continents.

OLX Autos operates more than 450 inspection centres across Asia and the Americas, and online trading platforms for people to buy and sell cars. To date, OLX Autos has bought, sold, and inspected more than 400,000 cars.

OLX Autos is currently active in Argentina, Chile, Colombia, Ecuador, India, Indonesia, Mexico and Peru. It operates under the well-known webuyanycar.com brand in the US, and CarFirst in Pakistan.

OLX Autos is part of OLX Group, which operates one of the fastest-growing networks of trading platforms globally. It serves 322 million people every month in 30+ countries around the world, helping them buy and sell cars, find housing, get jobs, buy and sell household goods, and much more. For more information, visit www.olxgroup.com.

About OLX Group

OLX Group operates one of the fastest-growing networks of trading platforms globally. Serving 322 million people every month in 30+ countries around the world, OLX Group helps them buy and sell cars, find housing, get jobs, buy and sell household goods, and much more. With more than 20 well-loved local brands including Avito, OLX, OLX Autos, Otomoto, and Property24, its solutions are built to be safe, smart, and convenient for its customers.

OLX Group is powered by a team of 11,000+ people around the world, who are unified in their ambition to shape the future of trade to unlock the hidden value in everything. For more information, visit www.olxgroup.com.

OLX Group is a division of Prosus, a global consumer internet group and one of the largest technology investors in the world. Prosus has a primary listing on Euronext Amsterdam (AEX:PRX) and a secondary listing on the JSE Limited (XJSE:PRX), and is majority-owned by Naspers. For more information on Prosus and its companies and investments, please visit www.prosus.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Abdallah Touqan
media@olxgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release

Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release

Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye